GU Highlights at
Ғылым және технология
Didn't get to ASCO this year?? Us neither!! But not to worry, we checked in with Dr Marty Schoen who did, and brings us all the key highlights! Marty is a GU Medical Oncologist at the St Louis Veterans Affairs Medical Centre and the University of St Louis, Missouri. He runs through a smattering of stuff that caught his eye at ASCO this year. Thanks Marty!
Also available as an audio podcast - just search GU Cast wherever you get your podcasts
Пікірлер: 3
Good to see Alice👍
Sequencing ARPIs in a control arm isn't debatable. It's unethical, based on Phase 2 data showing that the response rate for sequencing abiraterone followed by enzalutamide is only 30%, and for enzalutamide followed by abiraterone, a dismal 5-7%. Sequencing abiraterone and enzalutamide has shown it does not improve overall survival in several clinical trials. Using ARPI sequencing as a control arm because its suboptimal overestimates the benefits of whatever is being studied in comparison. Ensuring that control arms consistently represent the best current standard of care is essential to protecting patients and maintaining the integrity of the clinical trial process.
@gu_cast
15 күн бұрын
Totally agree! We have an interesting few comments coming on this in our upcoming APCCC Highlights part 2